Our Colon Cancer Gene Panel
North Central Florida Diagnostics & DNA Technologies (NCF DNA) brings the accessibility of genetic testing to individuals who have an increased risk of inherited colon and rectal cancer. Next Generation Sequence testing allows the identification of high-risk individuals and provides a key to early diagnosis of cancer and proactive care.
Using targeted genomic Next Generation Sequencing, we screen for germ-line mutations in 11 genes identified as conferring high risk for cancer as seen in individuals with colon and rectal carcinoma. This is a sub-panel of our comprehensive panel.
Our Colonectic TM panel consists of the following high-risk cancer genes: APC, BMPR1A, CDH1, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, SMAD4, STK11.
The increased cancer risk is due to inherited mutations that damage the self-repair capability of DNA. Factors suggestive of a genetic contribution to colorectal cancer include the following: (1) a strong family history of colorectal cancer and/or polyps;(2) early age at diagnosis of familial colorectal cancer (3) existence of other primary cancer. Additional factors coupled with family history includes history of diabetes, ulcerative colitis, and Crohn’s disease, diet high in fat and calories, low in fiber. Other factors include alcohol usage, smoking, lack of exercise and being overweight.